<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603460</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01808</org_study_id>
    <nct_id>NCT00603460</nct_id>
  </id_info>
  <brief_title>DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase-I/II Randomized Trial of Maintenance Vaccination Combined With Metronomic Cyclophosphamide w/wo Adoptive Transfer of CD3/CD28-CoStimulated T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer Previously Vaccinated DCVax-L</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwest Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with recurrent epithelial ovarian carcinoma or primary peritoneal cancer, who have&#xD;
      previously undergone vaccination in clinical study UPCC-11807 with DCVax-L, an autologous&#xD;
      vaccine with DC loaded in vitro with autologous tumor lysate.&#xD;
&#xD;
      Phase I Subjects enrolled in this study will receive leukapheresis; followed by&#xD;
      cyclophosphamide/fludarabine-induced lymphodepletion; followed by adoptive transfer of ex&#xD;
      vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells; followed by a&#xD;
      single DCVax-L vaccination, to establish feasibility and safety of this approach.&#xD;
&#xD;
      Primary Objectives of Phase I&#xD;
&#xD;
      To determine the feasibility and safety of administering vaccine-primed, ex vivo&#xD;
      CD3/CD28-costimulated autologous peripheral blood T cells in combination with DCVax-L&#xD;
      vaccination, following lymphodepletion with high dose cyclophosphamide/fludarabine.&#xD;
&#xD;
      Phase II&#xD;
&#xD;
      Twenty-two additional subjects will be randomized to receive either:&#xD;
&#xD;
        -  ARM-IIA: maintenance DCVax-L vaccination, in combination with oral metronomic&#xD;
           cyclophosphamide, or&#xD;
&#xD;
        -  ARM-IIB: leukapheresis, followed by cyclophosphamide/fludarabine-induced&#xD;
           lymphodepletion, followed by adoptive transfer of ex vivo CD3/CD28-costimulated&#xD;
           vaccine-primed peripheral blood autologous T cells, followed by maintenance DCVax-L&#xD;
           vaccination, plus oral metronomic cyclophosphamide.&#xD;
&#xD;
      Primary Objective of Phase II&#xD;
&#xD;
      To assess the distribution of progression-free survival at 6 months for patients treated with&#xD;
      maintenance DCVax-L vaccination plus oral metronomic cyclophosphamide as well as patients&#xD;
      treated with ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells&#xD;
      after lymphodepletion with high dose cyclophosphamide / fludarabine, followed by DCVax-L&#xD;
      boost vaccination and metronomic oral cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of treatment for Phase I:&#xD;
&#xD;
        -  Patients will be offered, if medically indicated, tumor resection or needle aspiration&#xD;
           of malignant effusion in order to make additional doses of DCVax-L vaccine.&#xD;
&#xD;
        -  If subjects have not received DCVax-L vaccination within the last 3-4 weeks, and if&#xD;
           DCVax-L is available, subjects have the option of receiving one dose of DCVax-L after&#xD;
           enrolment, to boost the frequency of vaccine-primed T cells.&#xD;
&#xD;
        -  Subjects will receive a single course of outpatient lymphodepleting chemotherapy with&#xD;
           intravenous cyclophosphamide (300 mg/m2/d for 3 days) and intravenous fludarabine (30&#xD;
           mg/m2/d for 3 days) both administered on days 8 to 10.&#xD;
&#xD;
        -  Ex vivo CD3/CD28-costimulated lymphocytes will be infused ~2 days after last day of&#xD;
           fludarabine infusion.&#xD;
&#xD;
        -  Patients will receive DCVax-L vaccine ~24-48 hrs after T cell infusion.&#xD;
&#xD;
        -  Subjects will be contacted every 6 months for 5 years for survival.&#xD;
&#xD;
      Description of treatment for Phase II:&#xD;
&#xD;
      In ARM-IIA:&#xD;
&#xD;
        -  Patients will be offered, if medically indicated, tumor resection or needle aspiration&#xD;
           of malignant effusion in order to make additional doses of DCVax-L vaccine.&#xD;
&#xD;
        -  Subjects will receive intradermal vaccinations with DCVax-L every 8 weeks, for four&#xD;
           cycles total. The first vaccine will be administered on day 0, which can be no sooner&#xD;
           than 4 weeks from previous DCVax-L vaccination related to clinical study UPCC-11807.&#xD;
&#xD;
        -  Subjects will receive oral cyclophosphamide at metronomic schedule and dose (50 mg&#xD;
           daily) every other week, starting ~3 weeks after DCVax-L in every vaccine cycle.&#xD;
&#xD;
        -  Patients will be offered (with the right to refuse) CT-guided needle biopsy or needle&#xD;
           aspiration of malignant effusion after the second vaccine.&#xD;
&#xD;
      In ARM-IIB:&#xD;
&#xD;
        -  Patients will be offered, if medically indicated, tumor resection or needle aspiration&#xD;
           of malignant effusion in order to make additional doses of DCVax-L vaccine.&#xD;
&#xD;
        -  Subjects will undergo ~10-15 liter leukapheresis to derive vaccine-primed peripheral&#xD;
           blood lymphocytes (PBL) on day 0. The apheresis material will be transferred to the Cell&#xD;
           and Vaccine Facility at the University of Pennsylvania (Penn CVPF) for T cell&#xD;
           manufacturing.&#xD;
&#xD;
        -  If subjects have not received DCVax-L vaccination within the last 3-4 weeks, and if&#xD;
           DCVax-L is available, subjects have the option of receiving one dose of DCVax-L after&#xD;
           enrolment, to boost the frequency of vaccine-primed T cells.&#xD;
&#xD;
        -  Subjects will receive a single course of outpatient lymphodepleting chemotherapy with&#xD;
           intravenous cyclophosphamide (300 mg/m2/d for 3 days) and intravenous fludarabine (30&#xD;
           mg/m2/d for 3 days).&#xD;
&#xD;
        -  Ex vivo CD3/CD28-costimulated lymphocytes will be infused ~2 days after last day of&#xD;
           fludarabine infusion.&#xD;
&#xD;
        -  Patients will receive DCVax-L vaccine boosts every 8 weeks for a total of four vaccines.&#xD;
           The first DCVax-L will be given ~24-48 hrs after T cell infusion.&#xD;
&#xD;
        -  Following DCVax-L, subjects will receive oral cyclophosphamide at metronomic schedule&#xD;
           and dose (50 mg daily) every other week x 3 cycles, starting ~3 weeks after DCVax-L in&#xD;
           every vaccine cycle.&#xD;
&#xD;
        -  Patients will be offered (with the right to refuse) CT-guided needle biopsy or needle&#xD;
           aspiration of malignant effusion ~1-2 weeks after the second vaccine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.</measure>
    <time_frame>Enrollment, 3 months after enrollment, End of study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVax-L and T Cells</intervention_name>
    <description>Arm A&#xD;
Optional DCVax-L prior to chemotherapy&#xD;
Apheresis&#xD;
Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)&#xD;
Infusion of activated T cells&#xD;
DCVax-L vaccine&#xD;
End of study visit&#xD;
Arm B&#xD;
Optional DCVax-L prior to chemotherapy&#xD;
Apheresis&#xD;
Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)&#xD;
Infusion of activated T cells&#xD;
DCVax-L vaccine&#xD;
Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks&#xD;
End of study visit</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Avastin</other_name>
    <other_name>DCVax-L</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous participation in UPCC 11807 (A Phase I Clinical Trial of Autologous Dendritic&#xD;
             Cell Vaccine Loaded with Autologous Tumor Cell Lysate for Recurrent Ovarian or Primary&#xD;
             Peritoneal Cancer)&#xD;
&#xD;
          -  PS &lt; 2&#xD;
&#xD;
          -  Subject must have tumor lysate sufficient to prepare at least 4 DCVax-L vaccines&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Life expectancy &gt; 4 months&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Normal organ and bone marrow function defined by:&#xD;
&#xD;
          -  ANC ≥ 1,000/μl&#xD;
&#xD;
          -  Platelets &gt;100,000/μl&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) &lt; 2.5 X institutional upper limit of normal&#xD;
&#xD;
          -  Bilirubin &lt;2.0 mg/dL unless secondary to bile duct blockage by tumor&#xD;
&#xD;
          -  Creatinine &lt;1.5 X the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with the following:&#xD;
&#xD;
          -  known brain metastases&#xD;
&#xD;
          -  renal insufficiency&#xD;
&#xD;
          -  liver failure&#xD;
&#xD;
          -  organ allograft&#xD;
&#xD;
          -  known autoimmune/collagen vascular disorders&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
&#xD;
          -  non-healing wounds, ulcers, or bone fractures&#xD;
&#xD;
          -  positive for serum anti-Yo (cdr2) antibodies&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within 6 months prior to registration&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Coukos, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

